Valuation: Prothena Corporation plc

Capitalization 48Cr 41Cr 37Cr 35Cr 65Cr 4.35TCr 68Cr 432.43Cr 171.19Cr 2.09TCr 179.87Cr 176.17Cr 7.53TCr P/E ratio 2025 *
-1.9x
P/E ratio 2026 * 15x
Enterprise value 48Cr 41Cr 37Cr 35Cr 65Cr 4.35TCr 68Cr 432.43Cr 171.19Cr 2.09TCr 179.87Cr 176.17Cr 7.53TCr EV / Sales 2025 *
47.5x
EV / Sales 2026 * 4.05x
Free-Float
86.54%
Yield 2025 *
-
Yield 2026 * -
More valuation ratios * Estimated data
Dynamic Chart
1 day+6.71%
1 week+1.14%
Current month+1.14%
1 month-2.41%
3 months-15.62%
6 months+15.41%
Current year-6.70%
More quotes
1 week 8.23
Extreme 8.23
9.05
1 month 8.23
Extreme 8.23
10.53
Current year 8.23
Extreme 8.23
10.53
1 year 4.32
Extreme 4.32
16.66
3 years 4.32
Extreme 4.32
79.65
5 years 4.32
Extreme 4.32
79.75
10 years 4.32
Extreme 4.32
79.75
More quotes
Manager TitleAgeSince
Chief Executive Officer 57 30/09/2016
Director of Finance/CFO 52 01/04/2013
Chief Tech/Sci/R&D Officer 53 01/01/2015
Director TitleAgeSince
Director/Board Member 72 20/12/2012
Director/Board Member 57 30/09/2016
Director/Board Member 63 01/08/2022
More insiders
Change 5d. change 1-year change 3-years change Capi.($)
+6.71%+1.14%-36.58%-84.42% 48Cr
-2.85%-1.17%+10.06%+99.89% 5.03TCr
+0.74%+2.76%+68.18%+6.68% 4.21TCr
-0.77%-4.47%+87.44%+617.03% 3.2TCr
+1.02%-6.27%-9.34%-24.98% 2.68TCr
+0.43%+1.84%+76.90%-41.54% 1.99TCr
-1.48%-3.17%+41.37%-27.43% 1.91TCr
+0.71%+1.88%+137.62% - 1.26TCr
-0.39%-8.61%+55.35%+118.87% 1.19TCr
Average +0.46%-1.54%+47.89%+83.01% 2.39TCr
Weighted average by Cap. -0.57%-1.22%+49.38%+120.39%
See all sector performances

Financials

2025 *2026 *
Net sales 1.01Cr 85.46L 78.33L 74.18L 1.38Cr 91Cr 1.44Cr 9.1Cr 3.6Cr 44Cr 3.79Cr 3.71Cr 158.51Cr 12Cr 10Cr 9.18Cr 8.7Cr 16Cr 1.07TCr 17Cr 106.7Cr 42Cr 516.14Cr 44Cr 43Cr 1.86TCr
Net income -25Cr -21Cr -19Cr -18Cr -34Cr -2.27TCr -36Cr -225.88Cr -89Cr -1.09TCr -94Cr -92Cr -3.93TCr -1.79Cr -1.51Cr -1.39Cr -1.31Cr -2.44Cr -161.8Cr -2.55Cr -16Cr -6.37Cr -78Cr -6.7Cr -6.56Cr -280.39Cr
Net Debt - -
More financial data * Estimated data
Logo Prothena Corporation plc
Prothena Corporation plc is an Ireland-based late-stage clinical biotechnology company. The Company is engaged in protein dysregulation and a pipeline of investigational therapeutics for rare peripheral amyloid diseases. The Company is advancing a pipeline of therapeutic candidates for a range of indications and targets to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins. The Company’s pipeline includes both wholly owned and partnered programs being developed for the potential treatment of diseases, including AL amyloidosis, ATTR amyloidosis, Alzheimer’s disease, Parkinson’s disease and a range of other neurodegenerative diseases. Its clinical programs include birtamimab for the potential treatment of AL amyloidosis, prasinezumab for the potential treatment of Parkinson’s disease, NNC6019/PRX004 for the potential treatment of ATTR amyloidosis, and PRX005 and PRX012 for the potential treatment of Alzheimer’s disease.
Employees
163
More about the company
Date Price Change Volume
06/26/06 8.910 $ +6.71% 5,81,028
05/26/05 8.350 $ -6.07% 5,18,973
04/26/04 8.890 $ +1.25% 4,51,843
03/26/03 8.780 $ -1.46% 2,80,865
02/26/02 8.910 $ +1.14% 5,56,687

Delayed Quote Nasdaq, February 07, 2026 at 02:30 am IST

More quotes
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
8.910USD
Average target price
20.33USD
Spread / Average Target
+128.21%
Consensus

Quarterly revenue - Rate of surprise